首页|Glucocorticoid therapy for acute respiratory distress syndrome:Current concepts
Glucocorticoid therapy for acute respiratory distress syndrome:Current concepts
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
Acute respiratory distress syndrome(ARDS),a fatal critical disease,is induced by various insults.ARDS rep-resents a major global public health burden,and the management of ARDS continues to challenge healthcare systems globally,especially during the pandemic of the coronavirus disease 2019(COV1D-19).There remains no confirmed specific pharmacotherapy for ARDS,despite advances in understanding its pathophysiology.Debate continues about the potential role of glucocorticoids(GCs)as a promising ARDS clinical therapy.Questions re-garding GC agent,dose,and duration in patients with ARDS need to be answered,because of substantial variations in GC administration regimens across studies.ARDS heterogeneity likely affects the therapeutic actions of exoge-nous GCs.This review includes progress in determining the GC mechanisms of action and clinical applications in ARDS,especially during the COVID-19 pandemic.
NETL
NSTL
万方数据
